EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review

Mohammad Ali Nilforoushzadeh, Nazila Heidari, Amirhossein Heidari, Yekta Ghane, Zahra Lotfi, Fariba Jaffary, Minou Najar Nobari, Niloufar Najar Nobari

International Immunopharmacology · 2024-04 · 131 · 111827

DOI: 10.1016/j.intimp.2024.111827 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-04. Verfasst von Mohammad Ali Nilforoushzadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Skin and Stem Cell Research Center, Tehran University of M…. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is an autoimmune-driven disease characterized by increased destruction and impaired platelet production resulting in an enhanced risk of bleeding. Immunosuppressant agents are the most common treatment strategies for ITP. Despite their efficacy, these medications often cause unpredictable side effects. Recent investigations revealed that patients with ITP exhibit elevated B-cell activating factor (BAFF) levels in both their spleens and serum. Belimumab, a BAFF inhibitor, illustrated a promising therapeutic avenue for managing ITP by interfering with BAFF activity and long-lived plasma cell production. Both clinical and experimental studies have yielded positive outcomes when combining rituximab with an anti-BAFF monoclonal antibody in treating ITP. In addition, ianalumab, a monoclonal antibody with a dual mechanism that targets BAFF-R and deletes peripheral BAFF-R+ B cells, is currently being used for ITP treatment [NCT05885555]. The upcoming results from novel BAFF inhibitors, such as ianalumab, could offer clinicians an additional therapeutic option for treating ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaHumansB-Cell Activating FactorInterleukin-4Antibodies, Monoclonal

Stichwörter der Autor:innen

B-cell activating factorBAFFBAFF inhibitorBelimumabITPIanalumabImmune thrombocytopenia

Substanzen

B-Cell Activating FactorInterleukin-4Antibodies, Monoclonal

Autor:innen und Institutionen

  • Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Mohammadalinilforou…
  • Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran; School of Medicine, Iran University of…
  • Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran; Faculty of Medicine, Tehran Medical Sci…
  • Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran; School of Medicine, Tehran University o…
  • Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: zlotfi1414@gmail.com.
  • Skin Repair Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Fjaffary@gmail.com.

Zitieren

APA

Nilforoushzadeh, M. A., Heidari, N., Heidari, A., Ghane, Y., Lotfi, Z., Jaffary, F., Najar Nobari, M., & Najar Nobari, N. (2024). The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review. International Immunopharmacology, 131, 111827. https://doi.org/10.1016/j.intimp.2024.111827

Vancouver

Nilforoushzadeh MA, Heidari N, Heidari A, Ghane Y, Lotfi Z, Jaffary F, et al. The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review. International Immunopharmacology. 2024;131:111827. doi:10.1016/j.intimp.2024.111827

BibTeX
@article{Nilforoushzadeh2024,
  author = {Nilforoushzadeh, Mohammad Ali and Heidari, Nazila and Heidari, Amirhossein and Ghane, Yekta and Lotfi, Zahra and Jaffary, Fariba and Najar Nobari, Minou and Najar Nobari, Niloufar},
  title = {The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {131},
  pages = {111827},
  doi = {10.1016/j.intimp.2024.111827}
}
Kostenlos starten →